JNJ-39758979 inhibits the signaling pathway between G-protein-coupled receptors (GPCRs) and G proteins. It targets guinea pig H4 receptor, human H4 receptor, monkey H4 receptor, mouse H4 receptor, and rat H4 receptor.
JNJ-39758979 can be used to research and develop therapeutic strategies for certain diseases that involve excessive activation of GPCR-G protein signaling pathways.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
